Regeneron Pharmaceuticals
Market Cap
US$32.6b
Last Updated
2019/08/19 23:41 UTC
Data Sources
Company Financials +
Executive Summary
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide.
Snowflake
Fundamentals
Flawless balance sheet and fair value.
Similar Companies
Share Price & News
How has Regeneron Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
0.8%
NasdaqGS:REGN
1.5%
US Biotechs
0.9%
US Market
1 Year Return
-20.4%
NasdaqGS:REGN
-7.3%
US Biotechs
0.3%
US Market
REGN underperformed the Biotechs industry which returned -8% over the past year.
REGN underperformed the Market in United States of America which returned -0.5% over the past year.
Share holder returns
| REGN | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.8% | 1.5% | 0.9% |
| 30 Day | 0.09% | 2.2% | -1.9% |
| 90 Day | -3.7% | 3.5% | 1.6% |
| 1 Year | -20.4%-20.4% | -6.5%-7.3% | 2.6%0.3% |
| 3 Year | -28.7%-28.7% | 8.9%5.2% | 41.0%31.8% |
| 5 Year | -14.2%-14.2% | 6.6%1.6% | 55.2%38.0% |
Price Volatility Vs. Market
How volatile is Regeneron Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
21 hours ago | Simply Wall St
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): What Are The Future Prospects?2 weeks ago | Simply Wall St
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): The Best Of Both Worlds3 weeks ago | Simply Wall St
Why Investors Should Run Towards Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Valuation
Is Regeneron Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?
22%
Discount to future cash flow value
Intrinsic Value Based on Future Cash Flows
Regeneron Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
Regeneron Pharmaceuticals's share price is below the future cash flow value, but not at a substantial discount (< 40%).
Price Based on Earnings
Regeneron Pharmaceuticals is good value based on earnings compared to the US Biotechs industry average.
Regeneron Pharmaceuticals is good value based on earnings compared to the United States of America market.
Price Based on Expected Growth
Regeneron Pharmaceuticals is poor value based on expected growth next year.
Price Based on Value of Assets
Regeneron Pharmaceuticals is overvalued based on assets compared to the US Biotechs industry average.
Next Steps
Future Growth
How is Regeneron Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 21 analysts?
6.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Regeneron Pharmaceuticals's revenue is expected to grow by 5.8% yearly, however this is not considered high growth (20% yearly).
Regeneron Pharmaceuticals's earnings are expected to grow by 6.9% yearly, however this is not considered high growth (20% yearly).
Regeneron Pharmaceuticals's revenue growth is positive but not above the United States of America market average.
Regeneron Pharmaceuticals's earnings growth is positive but not above the United States of America market average.
Regeneron Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Regeneron Pharmaceuticals is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
Next Steps
Past Performance
How has Regeneron Pharmaceuticals performed over the past 5 years?
37.8%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Regeneron Pharmaceuticals has delivered over 20% year on year earnings growth in the past 5 years.
Regeneron Pharmaceuticals's 1-year earnings growth is less than its 5-year average (30% vs 37.8%)
Regeneron Pharmaceuticals's earnings growth has not exceeded the US Biotechs industry average in the past year (30% vs 78.4%).
Return on Equity
Regeneron Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
Return on Assets
Regeneron Pharmaceuticals used its assets more efficiently than the US Biotechs industry average last year based on Return on Assets.
Return on Capital Employed
Regeneron Pharmaceuticals's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
Next Steps
Financial Health
How is Regeneron Pharmaceuticals's financial position?
Financial Position Analysis
Regeneron Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Regeneron Pharmaceuticals's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
Regeneron Pharmaceuticals has no debt.
Regeneron Pharmaceuticals has no debt compared to 5 years ago when it was 11.9%.
Regeneron Pharmaceuticals has no debt, it does not need to be covered by operating cash flow.
Regeneron Pharmaceuticals has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
High level of physical assets or inventory.
Regeneron Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Next Steps
Dividend
What is Regeneron Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Regeneron Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Regeneron Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Regeneron Pharmaceuticals has not reported any payouts.
Unable to verify if Regeneron Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Regeneron Pharmaceuticals has not reported any payouts.
Future Payout to Shareholders
No need to calculate the sustainability of Regeneron Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for United States of America.
Next Steps
Management
What is the CEO of Regeneron Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?
3.0yrs
Average management tenure
CEO
Schleifer Leonard S. (66yo)
31.6yrs
Tenure
US$26,520,555
Compensation
Dr. Schleifer Leonard S., M.D., Ph.D. founded Regeneron Pharmaceuticals, Inc. in 1988 and has been its President and Chief Executive Officer since 1988. Dr. Schleifer served as the Chairman of Regeneron Ph ...
CEO Compensation Analysis
Schleifer's remuneration is higher than average for companies of similar size in United States of America.
Schleifer's compensation has been consistent with company performance over the past year, both up more than 20%.
Management Age and Tenure
3.0yrs
Average Tenure
59yo
Average Age
The tenure for the Regeneron Pharmaceuticals management team is about average.
Board Age and Tenure
21.6yrs
Average Tenure
68.5yo
Average Age
The average tenure for the Regeneron Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Insider Trading
No 3 month open market individual insider trading information.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors Director |
| Shares | 1,000 |
| Max Price | US$305.93 |
| Entity | Company |
| Shares | 131,115 |
| Max Price | US$412.17 |
| Entity | Individual |
| Role | Chairman of the Board Chairman of the Board |
| Shares | 6 |
| Max Price | US$382.32 |
| Entity | Company |
| Shares | 104,552 |
| Max Price | US$406.68 |
Ownership Breakdown
Management Team
Schleifer Leonard S. (66yo)
Co-Founder
- Tenure: 31.6yrs
- Compensation: US$26.52m
George Yancopoulos (59yo)
Founding Scientist
- Tenure: 18.6yrs
- Compensation: US$25.38m
Joe LaRosa (60yo)
Executive VP
- Tenure: 7.9yrs
- Compensation: US$3.38m
Marion McCourt (59yo)
Senior VP & Head of Commercial
- Tenure: 1.5yrs
- Compensation: US$10.28m
Bob Landry (55yo)
Executive VP of Finance & CFO
- Tenure: 5.8yrs
- Compensation: US$9.36m
Beth Levine (55yo)
Senior VP
- Tenure: 0.6yrs
Daniel Van Plew (46yo)
Executive VP and GM of Industrial Operations & Product Supply
- Tenure: 11.3yrs
- Compensation: US$9.01m
Sally Paull
Senior Vice President of Human Resources
- Tenure: 3.3yrs
Hala Mirza
Senior Vice President of Corporate Communications & Citizenship
- Tenure: 0.6yrs
Justin Holko
Vice President of Investor Relations
- Tenure: 0.2yrs
Board Members
Chris Poon (67yo)
Director
- Tenure: 8.8yrs
- Compensation: US$1.23m
Pindaros Vagelos (89yo)
Chairman of the Board
- Tenure: 24.6yrs
- Compensation: US$6.35m
Schleifer Leonard S. (66yo)
Co-Founder
- Tenure: 31.6yrs
- Compensation: US$26.52m
George Yancopoulos (59yo)
Founding Scientist
- Tenure: 18.6yrs
- Compensation: US$25.38m
Art Ryan (76yo)
Director
- Tenure: 16.6yrs
- Compensation: US$1.23m
Michael Brown (78yo)
Director
- Tenure: 28.2yrs
- Compensation: US$1.23m
Joseph Goldstein (79yo)
Director
- Tenure: 28.2yrs
- Compensation: US$1.22m
George Sing (70yo)
Director
- Tenure: 31.6yrs
- Compensation: US$1.23m
Marc Tessier-Lavigne (59yo)
Director
- Tenure: 7.8yrs
- Compensation: US$1.21m
Bonnie Bassler (57yo)
Director
- Tenure: 2.9yrs
- Compensation: US$1.22m
Company Information
Regeneron Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Regeneron Pharmaceuticals, Inc.
- Ticker: REGN
- Exchange: NasdaqGS
- Founded: 1988
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$32.649b
- Shares outstanding: 109.42m
- Website: https://www.regeneron.com
Number of Employees
Location
- Regeneron Pharmaceuticals, Inc.
- 777 Old Saw Mill River Road
- Tarrytown
- New York
- 10591
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| REGN | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Apr 1991 |
| RGO | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Apr 1991 |
| REGN | SWX (SIX Swiss Exchange) | Yes | Common Stock | CH | CHF | Apr 1991 |
| 0R2M | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Apr 1991 |
| REGN * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Apr 1991 |
| REGN | WBAG (Wiener Boerse AG) | Yes | Common Stock | AT | EUR | Apr 1991 |
| REGN34 | BOVESPA (Bolsa de Valores de Sao Paulo) | BDR EACH 1 REP 0.2 COM USD0.001 | BR | BRL | May 2019 |
Biography
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company’s produ ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/08/19 23:41 |
| End of Day Share Price | 2019/08/19 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.